Our robust presence at ASH and SABCS reinforces Pfizer’s legacy of scientific innovation for people living with blood disorders and breast cancer,” said Chris Boshoff, Chief Oncology Officer and ...
The FDA advised that the on-going VIRAGE Phase 2b study should not be expanded into a Phase 3 study; rather, the optimal path forward for the VCN-01 PDAC program is to conduct a stand-alone Phase 3 ...